Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ZBIO with free AI briefings, catalyst countdowns, and dilution alerts.

ZBIO · Zenas BioPharma, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$647.1M Cash on Hand
33.7mo Cash Runway
Follow ZBIO by email Get an email when ZBIO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ZBIO, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoA
2027-05-27 Obexelimab IgG4-RD BLA 64%

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What ZBIO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Obexelimab Warm Autoimmune Hemolytic Anemia Phase 3 · NCT05786573 Active not recruiting
Orelabrutinib Multiple Sclerosis (MS) Primary Progressive Phase 3 · NCT07067463 Recruiting
ZB001 for injection Thyroid Eye Disease Phase 1 · NCT05776121 Completed
ZB002 Healthy Volunteers Phase 1 · NCT05638854 Completed
ZB004 Healthy Volunteers Phase 1 · NCT05794516 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ZBIO holds $647.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $57.6M/quarter from operations, an estimated runway of 33.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 24 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ZBIO files for a raise →

👥 Who Owns ZBIO

Insiders 30.9% Institutions (212 holders) 69.1% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 7,652,255 11.28% 2025-12-31
InnoCare Pharma Inc.
10% owner
Insider 7,000,000 10.32% 2026-08-26
Wellington Management Group LLP Institution (13G, 5%+) 6,566,134 9.68% 2026-08-31
SR ONE CAPITAL MANAGEMENT, LLC
10% owner
Insider 5,037,854 7.43% 2026-08-13
BlackRock, Inc. Institution (13G, 5%+) 3,287,021 4.85% 2026-09-30
Jason Raleigh Nunn
Director · +37,000 options
Insider 3,119,959 4.60% 2025-10-09
Fairmount Funds Management LLC
Director · +18,500 options
Insider 2,359,025 3.48% 2026-03-31
Leon O Jr Moulder
Chief Executive Officer, Director · +500,000 options
Insider 2,209,194 3.26% 2026-05-18
Patrick G Enright
Director · +37,000 options
Insider 786,520 1.16% 2025-10-09
Hongbo Lu
Director · +37,000 options
Insider 426,736 0.63% 2026-03-31
Patricia L Allen
Director · +37,000 options
Insider 19,860 0.03% 2026-02-12
Jennifer A. Fox
Chief Business Officer and Chief Financi · +275,000 options
Insider 1,592 0.00% 2026-06-15

Share count 67,817,793 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ZBIO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ZBIO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.